Summit Therapeutics Inc.
SMMTHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Summit Therapeutics Inc. (SMMT) is listed under Biotechnology. With a market capitalization of $11.70B, it sits in large-cap territory. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC).
Market Cap
$11.70B
Beta
-1.26
P/E (TTM)
—
P/E (Fwd)
-12.81
EPS (TTM)
$-1.55
EPS (Fwd)
$-1.18
ROE
-270.9%
ROA
-148.2%
Cash
$598.7M
Total Debt
$20.0M
Free CF
$69.9M
52W Change
-46.7%
Annual Financials
Cash vs Debt
Summit Therapeutics Inc. holds $598.7M in cash against $20.0M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company generates $69.9M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at -270.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $705K (2022) to $0 (2025), a 100% decline worth watching.
With a beta below 0.7, Summit Therapeutics Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Summit Therapeutics Inc.'s trajectory.